Today, representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter brand and generic manufacturers; pharmacies and pharmacists across all practice settings, including health systems and hospitals, community, specialty, and managed care; supermarkets; wholesalers; pharmaceutical quality standard developers; employers and other health plan sponsors; health insurance providers; and pharmacy benefit managers, released guiding principles for the safe efficacious development, distribution, and allocation of vaccine(s) to achieve mass immunization against the coronavirus (COVID-19).
The efficient, well-coordinated distribution, allocation, and mass vaccination activities against the novel coronavirus (SARS-CoV-2) will help ensure vaccination is an effective countermeasure to the current pandemic.
This week, AMCP Nexus 2020 Virtual will welcome more than 1,800 managed care pharmacy professionals from across the country for five days of focused, essential learning opportunities centered on “making the way for innovation” in managed care pharmacy.
On Oct. 5, AMCP submitted comments about the Part D MTM program, specifically in regards to the ability of plan sponsors and MTM vendors to provide annual CMR to individuals other than the beneficiary in certain circumstances in which the beneficiary is unable to participate.
Sponsored webinar that reframed the landscape of Chemotherapy-induced myelosuppression (CIM) with a fresh perspective on the root of the clinical problem, the patient burden revealed through real world management of CIM, and the hope for a future that fulfills the unmet need – one made more complicated by the confounding influence of Covid-19 in the day-to-day management of people facing malignancy.